within Pharmacolibrary.Drugs.ATC.B;

model B02AA02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0018333333333333333,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B02AA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing blood clots. It is primarily used to treat or prevent excessive bleeding in various medical conditions, including during surgery, trauma, heavy menstrual bleeding (menorrhagia), and in certain bleeding disorders. Tranexamic acid is approved for use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>Single-dose intravenous administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Grassin-Delyle, S, Semeraro, M, Lamy, E, Urien, S, Runge, I, Foissac, F, Bouazza, N, Treluyer, JM, Arribas, M, Roberts, I, &amp; Shakur-Still, H (2022). Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. <i>British journal of anaesthesia</i> 128(3) 465–472. DOI:<a href=&quot;https://doi.org/10.1016/j.bja.2021.10.054&quot;>10.1016/j.bja.2021.10.054</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34998508/&quot;>https://pubmed.ncbi.nlm.nih.gov/34998508</a></p></li><li><p>González Osuna, A, Rojas, LF, Lamas, C, Aguilera Roig, X, Pla-Junca, F, Videla, S, Martínez-Zapata, MJ, &amp; Valle, M (2022). Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. <i>Clinical pharmacokinetics</i> 61(1) 83–95. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01043-9&quot;>10.1007/s40262-021-01043-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34255299/&quot;>https://pubmed.ncbi.nlm.nih.gov/34255299</a></p></li><li><p>DeSoucy, ES, Davidson, AJ, Hoareau, GL, Simon, MA, Tibbits, EM, Ferencz, SE, Grayson, JK, &amp; Galante, JM (2019). Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model. <i>Journal of special operations medicine : a peer reviewed journal for SOF medical professionals</i> 19(4) 80–84. DOI:<a href=&quot;https://doi.org/10.55460/COGQ-2CY1&quot;>10.55460/COGQ-2CY1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31910476/&quot;>https://pubmed.ncbi.nlm.nih.gov/31910476</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B02AA02;
